| Interactions between Xenobiotics and DME (XEOTIC)
|
| Health or Environmental Toxicant(s) |
| Acute Toxic Substance |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Paraquat |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01422
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Paraquat up-regulates the expression of DME LPO |
[1] |
| Pharmaceutical Agent(s) |
| Approved/Marketed Drug |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Cisplatin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00334
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cisplatin inhibits the expression of DME LPO |
[2] |
| Drug in Phase 1 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
|
| Lanthanum Chloride Hydroxide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00680
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Lanthanum Chloride Hydroxide up-regulates the expression of DME LPO |
[3] |
| Naringenin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00573
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Naringenin induces the drug-metabolizing activity of DME LPO |
[4] |
|
|
|
|
|
|